Ranibizumab for Neovascularization in Sickle Cell Retinopathy

NAWithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2010

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Sickle Cell AnemiaRetinopathy
Interventions
DRUG

Ranibizumab

Ranibizumab 0.5 mg intravitreal injection

Trial Locations (1)

48201

Kresge Eye Institute, Detroit

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Wayne State University

OTHER

collaborator

Genentech, Inc.

INDUSTRY

lead

Kresge Eye Institute

OTHER